Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $259 million in 2023 and is poised to reach $349 million by 2028, growing at a CAGR of 6.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. Rising demand for personalized medicine is one of the prominent driving factor of the humanized mouse and rat model market. Existing mouse models have certain limitations in predictive research, unable to effectively gauge response in human cancer patients. Therefore, research institutes and academic institutes are focused on the development of advanced innovative models. Demand for personalized medicine is further driven by advancements in proteomics, genomics, and metabolomics. Additionally demand for targeted diagnostics and preventive medicine are propelling the demand for humanized mouse and rat research models.
Download an Illustrative overview:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955
Browse in-depth TOC on "Humanized Mouse and Rat Model Market"
140 - Tables
27 - Figures
188 – Pages
The genetic models dominated the humanized mouse and rat model market in 2022.
Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. The humanized mouse models segment is further divided into genetic humanized mouse models and cell-based humanized mouse models. The genetic models generated highest revenue in 2022. In genetic humanized mouse models, the human protein/domain is expressed while the mouse protein/domain is suppressed in all cells and tissues. Genetic humanized mouse models have been successfully adopted in analyzing biological efficacy, safety testing, pharmaceutical compounds, and studying novel therapeutics. Humanized mouse models are gaining demand in studies around drug metabolism and immune system development & functioning.
The oncology segment represented a dominant share in the market in 2022.
Based on application, the humanized mouse and rat model market is segmented into toxicology, oncology, immunology and infectious diseases, hematopoiesis, neuroscience, and other applications. Humanized models mimic human cancers and act as essential platforms for cancer research. Cancer research involves studying cancer biology and understanding or predicting cancer, including tumor characterization, tumorigenesis, and metastasis. The growth of this segment can be attributed to the growing number of cancer research programs in academic & research institutes and favorable support by governments for cancer research.
The Asia Pacific region is the fastest-growing region of the humanized mouse and rat model market throughout the forecast period.
Based on the region, the humanized mouse and rat model market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is estimated to register the highest growth during the forecast period. Increase in demand for market products across China and India is the key contributive factor. Led by growing R&D activities, the outsourcing of preclinical, clinical, and laboratory testing services for small & large molecules is expected to increase in the country. The growing pharmaceutical industry, the rising number of CROs, and rising research activities will drive the growth of China's humanized mouse and rat model market.
Request 10% Customization:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=131763955
Humanized Mouse and Rat Model Market Dynamics:
Drivers:
- Increasing research activities using humanized models
- Rising demand for personalized medicine
- Continuous support and initiatives from government and private sectors for cancer research
- Growing R&D activities in pharmaceutical and biotechnology sectors
Restraints:
- High cost of custom humanized models
- Laws and regulations for ethical use of animal models in research
Opportunities:
- Rising demand for humanized PDX models
- Emergence of CRISPR as a powerful tool in biomedical research
- Rising demand for humanized rat models
Challenges:
- Alternatives for animal testing
- Limitations of humanized mouse models
Key Market Players:
The prominent players in the global humanized mouse and rat model market include Charles River Laboratories (US), THE JACKSON LABORATORY (JAX) (US), Taconic Biosciences, Inc. (US), Crown Biosciences (US), Champions Oncology, Inc. (US), Hera BioLabs (US), genOway (France), Inotiv (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), TRANS GENIC (Japan), Harbour Antibodies BV (Netherlands), Oncodesign (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure services (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US).
CHARLES RIVER LABORATORIES (US)
Charles River Laboratories (US) ranks second in terms of market position, attributive to its established range of mice models and rat models in the market. CRL is operational since more than 70 years, and has achieved core competency in vivo biology. The company provides early-stage drug discovery and preclinical development solutions, including humanized mouse models. Its robust portfolio helps the company to strengthen collaboration with clients—from early lead generation to candidate selection. CRL’s portfolio is inclusive of around 150 different stocks and strains of animal models, the company is engaged in producing and selling the most widely used rodent research model strains and purpose-bred rats and mice. Charles River also provides a variety of related services that are designed to support clients in the use of research models in drug discovery and development.
INOTIV (US)
Inotiv is one of the leading market players in the mice model market. The strength of the company can be attributed to its robust product portfolio as well as a number of acquisitions & partnerships that allows it to market its products worldwide. Inotiv also has a significant geographical footprint in developed countries across North America and Europe. Inotiv entered the mice model market with the acquisition of Envigo. Since this strategic development, the company has worked towards improving its production & distribution capabilities. The company’s revenue grew to USD 547.7 million during the fiscal year 2022 from USD 89.6 million during the fiscal year 2021.
Recent Developments:
- In January 2022, Taconic Biosciences, Inc. (US) launched the huNOG-EXL EA (early access) humanized immune system (HIS) mouse.
- In October 2021, The Jackson Laboratory (US) acquired RMS Business of Charles River Laboratories Japan, Inc. (Japan) which is Charles River Laboratories Japan's Research Models & Services (RMS) business as a wholly-owned subsidiary.
- In September 2021, Biocytogen (US) collaborated with Envigo (US) in order to support the research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the US, Europe, and certain APAC regions.
- In March 2021, Charles River Laboratories International, Inc. (US) acquired Cognate BioServices, Inc. (US) a cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies. The acquisition expanded Charles River's broad capabilities across the major CDMO platforms for cell and gene therapies.
Report Link: ( Humanized Mouse and Rat Model Market )
Humanized Mouse and Rat Model Market Advantages:
- Predictive Validity: Humanized models closely mimic human physiology, genetics, and immune responses, providing a more accurate representation of human disease progression and treatment outcomes. This predictive validity enhances the reliability of preclinical data and improves the likelihood of successful translation to clinical trials.
- Reduced Ethical Concerns: Using humanized models reduces the need for animal testing on non-human species, addressing ethical concerns and promoting more humane research practices.
- Personalized Medicine: These models can be customized to replicate specific patient profiles or disease conditions, enabling personalized medicine approaches for tailored treatment strategies.
- Drug Efficacy and Safety Screening: Humanized models allow for rigorous assessment of drug efficacy and safety before progressing to human clinical trials, reducing the risk of adverse effects and optimizing the drug development process.
- Understanding Disease Mechanisms: By closely resembling human biology, these models offer valuable insights into disease mechanisms and underlying molecular pathways, advancing our understanding of complex diseases.
- Rapid and Cost-Effective Research: Humanized models can accelerate research timelines by providing faster results compared to traditional animal models. This efficiency reduces overall research costs and expedites the discovery of novel therapies.
- Translatability to Humans: The ability of humanized models to recapitulate human responses enhances the likelihood of successful translation of research findings to human patients, fostering more effective treatments.
- Targeted Therapies: Humanized models facilitate the evaluation of targeted therapies by replicating the specific molecular targets present in human diseases, aiding in the development of precision medicine approaches.
- Infectious Disease Research: Humanized models are particularly valuable in studying infectious diseases, allowing researchers to study pathogen-host interactions and test potential vaccines and antiviral treatments.
- Academic and Industry Collaboration: The widespread adoption of humanized models fosters collaboration between academic institutions, pharmaceutical companies, and biotech firms, encouraging a dynamic exchange of knowledge and resources to advance medical research collectively.
Overall, the humanized mouse and rat model market represents a pivotal advancement in the biomedical field, enabling researchers to overcome the limitations of traditional models and paving the way for more effective and personalized medical interventions in the future.
About MarketsandMarkets™:
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/humanized-mouse-model-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/humanized-mouse-model.asp